Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy.

Mitochondrion · 2017 · PMC5644719 · PMID 28093355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The RHODOS trial failed to show a benefit for its pre-specified primary end point (best recovery of visual acuity at week 24), but all of the secondary end points showed a positive trend towards visual improvement in the idebenone-treated group ( Klopstock et al., 2011 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.